UT-MD Anderson Cancer Center: Most Patients With Advanced Melanoma Who Received Pre-surgical Immunotherapy Remain Alive and Disease Free Four Years Later
July 11, 2025
July 11, 2025
HOUSTON, Texas, July 11 (TNSjou) -- The University of Texas MD Anderson Cancer Center issued the following news release:
* * *
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
* Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
* 87% of patients remained alive and 80% were disease free four years after trea . . .
* * *
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
* Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
* 87% of patients remained alive and 80% were disease free four years after trea . . .